| NCT ID | NCT05488522 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Condition | Hepatocellular Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 18 participants |
| Start Date | 2022-09-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 18 participants in total. It began in 2022-09-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with concurrent atezolizumab and bevacizumab for patients with advanced hepatocellular carcinoma (HCC)
Eligibility Criteria
Inclusion Criteria: * Subjects must have hepatocellular carcinoma (HCC) that is not amenable to curative-intent surgical or ablation (where surgery or ablation are not indicated due to disease extent, co-morbidities, or other technical reasons) and systemic therapy is indicated. Exclusion Criteria: \-
Contact & Investigator
Edgar Ben-Josef, MD
PRINCIPAL INVESTIGATOR
Abramson Cancer Center
Frequently Asked Questions
Who can join the NCT05488522 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05488522 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05488522 currently recruiting?
Yes, NCT05488522 is actively recruiting participants. Contact the research team at edgar.ben-josef@pennmedicine.upenn.edu for enrollment information.
Where is the NCT05488522 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT05488522 clinical trial?
NCT05488522 is sponsored by Abramson Cancer Center at Penn Medicine. The principal investigator is Edgar Ben-Josef, MD at Abramson Cancer Center. The trial plans to enroll 18 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.